论文部分内容阅读
目的:观察柴胡鳖甲汤联合常规抗病毒治疗病毒性乙型肝炎的临床效果。方法:将我院自2013年2月~2015年2月收治的80例病毒性乙型肝炎患者作为研究对象,按随机序贯法分为对照组与观察组2组,对照组给予常规抗病毒疗法,观察组则对照组基础上加用柴胡鳖甲汤,2组均连续治疗4周,比较治疗前后2组ALT(丙氨酸转氨酶)、AST(谷草转氨酶)水平的变化情况,统计2组临床疗效,观察2组治疗的安全性,统计2组中医症候积分的改善情况。结果:观察组显效12例,有效10例,好转3例,总有效率为87.5%,与对照组的50.0%对比差异有统计学意义(P<0.05);治疗后,观察组ALT、AST、中医积分分别为(42.3±21.5)IU/L、(39.4±19.8)IU/L、(7.0±2.2)分,与对照组相比差异有统计学意义(P<0.05);观察组治疗不良反应发生率为5.0%,与对照组的27.5%对比差异有统计学意义(P<0.05)。结论:在病毒性乙型肝炎患者的临床治疗中,采用柴胡鳖甲汤联合常规抗病毒治疗方案,临床治疗有效率高,患者肝功能指标明显改善,且不良反应发生率低,安全性高,值得推广。
Objective: To observe the clinical effect of Chaihu Biejia Decoction combined with conventional antiviral treatment of viral hepatitis B. Methods: Eighty patients with viral hepatitis B admitted from February 2013 to February 2015 in our hospital were divided into two groups: control group and observation group according to randomized sequential method. The control group was given routine antiviral The observation group was treated with Bupleurum Chinensis and Biejia Decoction on the basis of the control group, and the two groups were treated for 4 weeks continuously. The changes of ALT and AST were compared before and after treatment. Statistics 2 The clinical efficacy was observed. The safety of treatment in two groups was observed. The improvement of TCM symptom scores in two groups was statistically analyzed. Results: The observation group was significantly improved in 12 cases, effective in 10 cases, improved in 3 cases, the total effective rate was 87.5%, compared with 50.0% in the control group, the difference was statistically significant (P <0.05); after treatment, ALT, AST, The score of TCM was (42.3 ± 21.5) IU / L, (39.4 ± 19.8) IU / L and (7.0 ± 2.2) points respectively. There was significant difference between the two groups (P <0.05) The incidence was 5.0%, compared with 27.5% in the control group, the difference was statistically significant (P <0.05). Conclusion: In the clinical treatment of patients with viral hepatitis B, Bupleurum and Biejia Decoction combined with routine antiviral treatment regimen, clinical treatment of high efficiency, patients with significantly improved liver function indicators, and the incidence of adverse reactions, high safety , Worth promoting.